BMAC – Biopharmaceutical Manufacturer's Advisory Council
An initiative by leading Biopharmaceutical companies in the world to establish Singapore as the country of choice for global biomedical sciences manufacturing.
MSD’s Singapore operations are proving that life-saving science can go hand in hand with ambitious climate action.
At its manufacturing site here, the global healthcare company has made energy efficiency and carbon reduction part of daily operations, setting a clear benchmark for environmental stewardship in the industry.
MSD (NYSE: MRK), known as Merck & Co., Inc., Kenilworth, NJ, USA in the United States and Canada today announced that LAGEVRIO® (molnupiravir), an oral antiviral treatment for adults with mild to moderate COVID-19 has received interim authorization by the Health Sciences Authority (HSA) under the Pandemic Special Access Route (PSAR).
MSD Committed 91.5 Million Doses of Human Papillomavirus (HPV) Vaccine for Use in Gavi-Supported Countries